Latest / Stock Movers / Novo Nordisk Drops, Puma Down, Trainline Rises
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios. Podcasts. Radio. News. The Stock Movers Report.
- 0:10Speaker 1: Your roundup of companies making moves in the stock market.
- 0:13Speaker 1: Harnessing the power of Bloomberg data.
- 0:16Speaker 2: Now let's take a look at some of the stocks
- 0:18Speaker 2: on the move today in Europe.
- 0:20Speaker 1: I'm Charles Capel with Caroline Hepker.
- 0:22Speaker 2: We're joined by Bloomberg reporter Chloe Millay.
- 0:24Speaker 1: Chloe, a drop for Novo Nordisk. What's the story?
- 0:27Speaker 2: Yes. So, Novo just got downgraded by Morgan Stanley Analyst
- 0:31Speaker 2: to a sell rating. So, those analysts have said they
- 0:33Speaker 2: were quite concerned about subdued growth prospects for the company
- 0:38Speaker 2: and said that those were not reflected currently in the
- 0:41Speaker 2: valuation for Novo. And so, the big problem really is
- 0:44Speaker 2: the patent cliff that is facing GLP-1s in some markets
- 0:48Speaker 2: like the U.S. and Europe, where generic competition is going
- 0:52Speaker 2: to start coming quite soon. So, about the mid-2030s is
- 0:55Speaker 2: going to start happening. And of course, this loss of
- 0:58Speaker 2: exclusivity on some of those drugs is going to be
- 1:01Speaker 2: a huge challenge for Novo Nordisk and some of its
- 1:04Speaker 2: peers as well. And so, this latest downgrade now brings
- 1:07Speaker 2: the overall number of sell ratings on that stock at five. So,
- 1:13Speaker 2: that's quite a lot given that they are just nine buys.
- 1:17Speaker 2: And recently, Deutsche Bank analysts also cut their recommendation on Novo,
- 1:21Speaker 2: saying there was very high uncertainty surrounding the outlook for
- 1:25Speaker 2: the company. They said, you know, the latest results were
- 1:28Speaker 2: quite messy. The weight loss pill did not manage to
- 1:30Speaker 2: beat expectations. And there were a lot of hope essentially
- 1:34Speaker 2: placed in this Wegovy pill. And there have also been
- 1:38Speaker 2: some recent trial setbacks. So, there's been quite a few
- 1:40Speaker 2: challenges there. And the attention now is really turning on
- 1:44Speaker 2: September 21st, when Novo will have its capital markets day. So,
- 1:48Speaker 2: we'll see if any further catalysts emerge and if it
- 1:51Speaker 2: can reassure investors.
- 1:52Speaker 1: Interesting. Novo Nordisk. Okay. What about the news from Puma? Yes.
- 1:58Speaker 2: So, management uncertainty there for Puma. So, the chief commercial
- 2:01Speaker 2: officer will be stepping down on September 30th for personal reasons.
- 2:06Speaker 2: This adds a little bit of uncertainty on the strategy
- 2:09Speaker 2: given that Puma is currently in the middle of a
- 2:12Speaker 2: big turnaround. So, the latest results showed that some progress
- 2:16Speaker 2: had been made on this reset, the strategic reset. But
- 2:20Speaker 2: the sales are still likely to continue being very weak
- 2:23Speaker 2: throughout the rest of this year of 2026 with The
- 2:27Speaker 2: focus being mainly on clearing the inventory and the hope
- 2:31Speaker 2: that things that can sort of get back on track
- 2:33Speaker 2: starting in 2027. It's been quite a tough time overall
- 2:37Speaker 2: for those sportswear stocks. We had Lululemon cutting its guidance recently.
- 2:42Speaker 2: Nike and Adidas are struggling to get back in investors'
- 2:45Speaker 2: good graces. And so, for Puma, there is this kind
- 2:48Speaker 2: of broader sector weakness and then this additional uncertainty from
- 2:53Speaker 2: this management change as well, weighing a little bit on
- 2:55Speaker 2: the shares this morning.
- 2:57Speaker 1: And finally, Trainline has released its latest forecast. Tell us more.
- 3:01Speaker 2: Yeah, so quite a solid trading update this morning from Trainline.
- 3:04Speaker 2: Strong results in the first half. a new buyback of
- 3:07Speaker 2: £ 100 million and also maintained its guidance. So, analysts have
- 3:12Speaker 2: noted that the passenger volumes were quite resilient, that rail
- 3:15Speaker 2: demand was quite strong. There have been some challenges. And
- 3:19Speaker 2: of course, the extreme heat that we've seen in Europe
- 3:22Speaker 2: has hurt the demand in some parts of the international business.
- 3:27Speaker 2: But the UK business is looking actually in pretty good shape.
- 3:31Speaker 2: What's weighed on the shares recently for Train9 was that
- 3:34Speaker 2: the UK's Competition and Markets Authority said last month it
- 3:38Speaker 2: was investigating a few firms, including Trainline, over drip pricing,
- 3:44Speaker 2: which is when a company advertises a low initial price
- 3:48Speaker 2: and then slowly adds, you know, fees on top of that, taxes,
- 3:51Speaker 2: service charges, etc. And so, that investigation into Trainline has been,
- 3:56Speaker 2: you know, creating some weaknesses. in the shares. So this
- 3:59Speaker 2: trading update has helped to relieve some of that pressure.
- 4:03Speaker 2: But we're still down about 10% year to date for
- 4:06Speaker 2: the company.
- 4:07Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 4:11Speaker 1: us throughout the day for the latest roundup of companies
- 4:14Speaker 1: making news on Wall Street. And for the latest market
- 4:17Speaker 1: moving headlines, listen to Bloomberg Radio live. Catch us on YouTube,
- 4:22Speaker 1: Bloomberg.com and on Apple CarPlay and Android Auto with the
- 4:26Speaker 1: Bloomberg Business app.